UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

Nature structural & molecular biology, 2004-12, Vol.11 (12), p.1192-1197

2004

Volltextzugriff (PDF)

The contribution of HRD to tourism-led development in an African context

South African journal of economic and management sciences, 2006-12, Vol.9 (4), p.444-457

2006

Volltextzugriff (PDF)

Relationship between Organizational Climate, Employee Psychological Empowerment, and Innovation in Market Research Firms in Kenya

Applied Finance and Accounting, 2017-10, Vol.4 (1), p.11

2017

Volltextzugriff (PDF)

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

Nature medicine, 1999-07, Vol.5 (7), p.810-816

1999

Volltextzugriff (PDF)

Top Management Team Demographic Diversities, Generic Strategy and Firm Performance in Marketing Social Research Association (MSRA) in Kenya

Applied Finance and Accounting, 2016-05, Vol.2 (2), p.30

2016

Volltextzugriff (PDF)

The pharmacology of the novel and selective sigma ligand, PD 144418

Neuropharmacology, 1997, Vol.36 (1), p.51-62

1997

Volltextzugriff (PDF)

In vitro and in vivo evaluation of the subtype-selective muscarinic agonist PD 151832

Life sciences (1973), 1995, Vol.56 (11), p.845-852

1995

Volltextzugriff (PDF)

Synthesis and Sar of bulky 1-azabicyclo[2.2.1]-3-one oximes as muscarinic receptor subtype selective agonists

Life sciences (1973), 1993, Vol.52 (5), p.505-511

1993

Volltextzugriff (PDF)

Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization

The Journal of pharmacology and experimental therapeutics, 1999-11, Vol.291 (2), p.812

1999

Volltextzugriff (PDF)

CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology

Pharmaceutica acta Helvetiae, 2000-03, Vol.74 (2-3), p.141-148

2000

Volltextzugriff (PDF)

A rationale for the design and synthesis of m1 selective muscarinic agonists

Bioorganic & medicinal chemistry letters, 1992-08, Vol.2 (8), p.821-826

1992

Volltextzugriff (PDF)

(±)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-methyl-5-aryl-2-penten-4-ynyl) oximes: Potent muscarinic agonists

Bioorganic & medicinal chemistry letters, 1995-03, Vol.5 (6), p.637-642

1995

Volltextzugriff (PDF)

Z-(±)-1-azabicyclo[2.2.1]heptan-3-one, O-(3-aryl-2-propynyl) oximes as potential m1-subtype selective muscarinic agonists

Bioorganic & medicinal chemistry letters, 1995-03, Vol.5 (6), p.631-636

1995

Volltextzugriff (PDF)

4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties

Journal of medicinal chemistry, 1990-01, Vol.33 (1), p.311-317

1990

Volltextzugriff (PDF)

Design and Synthesis of m1-Selective Muscarinic Agonists: (R)-(−)-(Z)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-(3‘-Methoxyphenyl)-2-propynyl)- oxime Maleate (CI-1017), a Functionally m1-Selective Muscarinic Agonist

Journal of medicinal chemistry, 1998-07, Vol.41 (14), p.2524-2536

1998

Volltextzugriff (PDF)

Effect of mutating aspart ate 103 to glutamate or asparagine in the Hm2 subtype on binding of agonists and antagonists of varied pKa and subtype selectivity

Life sciences (1973), 1995-02, Vol.56 (11-12), p.1020

1995

Volltextzugriff (PDF)

Effect of mutating aspart ate 103 to glutamate or asparagine in the Hm2 subtype on binding of agonists and antagonists of varied pK a and subtype selectivity

Life sciences (1973), 1995, Vol.56 (11), p.1020-1020

1995

Volltextzugriff (PDF)

Mutations of aspartate 103 in the Hm2 receptor and alterations in receptor binding properties of muscarinic agonists

Life sciences (1973), 1995, Vol.56 (11), p.923-929

1995

Volltextzugriff (PDF)

Characterization of muscarinic agonists in recombinant cell lines

Life sciences (1973), 1993, Vol.52 (5), p.465-472

1993

Volltextzugriff (PDF)

Development of M1 subtype selective muscarinic agonists for Alzheimer's disease: Translation of in vitro selectivity into in vivo efficacy

Drug development research, 1997-02, Vol.40 (2), p.133-143

1997

Volltextzugriff (PDF)

Molecular modeling studies of the m1 and m2 muscarinic receptors leading to the design of selective m1 agonists

Life sciences (1973), 1993, Vol.52 (5), p.561-561

1993

Volltextzugriff (PDF)

Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease

Progress in brain research, 1993, Vol.98, p.439-445

1993

Volltextzugriff (PDF)

Development of M1 subtype selective muscarinic agonists for Alzheimer's disease : Translation of in vitro selectivity into in vivo efficacy: Challenges and opportunities for developing muscarinic receptor subtype-based therapeutic agents

Drug development research, 1997, Vol.40 (2), p.133-143

1997

Volltextzugriff (PDF)

EFFICIENT SYNTHESIS OF EXO-1-AZABICYCLO[2.2.1]HEPTAN-3-OL

Organic preparations and procedures international, 1997-06, Vol.29 (3), p.330-335

1997

Volltextzugriff (PDF)

Aryleneyne 1-azabicyclo[2.2.1]heptan-3-one oximes: Potent muscarinic agonists

Life sciences (1973), 1995-02, Vol.56 (11), p.1003-1003

1995

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(65)
Buchkapitel
(3)

Sprache

Englisch
(68)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

The contribution of HRD to tourism-led development in an African context

Relationship between Organizational Climate, Employee Psychological Empowerment, and Innovation in Market Research Firms in Kenya

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

Top Management Team Demographic Diversities, Generic Strategy and Firm Performance in Marketing Social Research Association (MSRA) in Kenya

The pharmacology of the novel and selective sigma ligand, PD 144418

In vitro and in vivo evaluation of the subtype-selective muscarinic agonist PD 151832

Synthesis and Sar of bulky 1-azabicyclo[2.2.1]-3-one oximes as muscarinic receptor subtype selective agonists

Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization

CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology

A rationale for the design and synthesis of m1 selective muscarinic agonists

(±)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-methyl-5-aryl-2-penten-4-ynyl) oximes: Potent muscarinic agonists

Z-(±)-1-azabicyclo[2.2.1]heptan-3-one, O-(3-aryl-2-propynyl) oximes as potential m1-subtype selective muscarinic agonists

4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties

Design and Synthesis of m1-Selective Muscarinic Agonists: (R)-(−)-(Z)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-(3‘-Methoxyphenyl)-2-propynyl)- oxime Maleate (CI-1017), a Functionally m1-Selective Muscarinic Agonist

Effect of mutating aspart ate 103 to glutamate or asparagine in the Hm2 subtype on binding of agonists and antagonists of varied pKa and subtype selectivity

Effect of mutating aspart ate 103 to glutamate or asparagine in the Hm2 subtype on binding of agonists and antagonists of varied pK a and subtype selectivity

Mutations of aspartate 103 in the Hm2 receptor and alterations in receptor binding properties of muscarinic agonists

Characterization of muscarinic agonists in recombinant cell lines

Development of M1 subtype selective muscarinic agonists for Alzheimer's disease: Translation of in vitro selectivity into in vivo efficacy

Molecular modeling studies of the m1 and m2 muscarinic receptors leading to the design of selective m1 agonists

Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease

Development of M1 subtype selective muscarinic agonists for Alzheimer's disease : Translation of in vitro selectivity into in vivo efficacy: Challenges and opportunities for developing muscarinic receptor subtype-based therapeutic agents

EFFICIENT SYNTHESIS OF EXO-1-AZABICYCLO[2.2.1]HEPTAN-3-OL

Aryleneyne 1-azabicyclo[2.2.1]heptan-3-one oximes: Potent muscarinic agonists

Suchergebnisse filtern